Source:http://linkedlifedata.com/resource/pubmed/id/11396630
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2001-6-8
|
| pubmed:abstractText |
Matrix metalloproteinases (MMPs) are proteolytic enzymes important at several points during multistep neoplastic progression. Although MMP-1 and MMP-3 have been implicated in the progression of various human cancers, their expression in bladder cancer has not been addressed. Immunohistochemistry (Strept-ABC-HRP method) and in situ hybridization were performed to detect MMP-1 protein, MMP-3 protein, and MMP-3 mRNA, respectively, in 59 transitional cell bladder carcinomas. To assess the role of these MMPs in bladder cancer, their expression was evaluated in relation to known clinicopathologic parameters and patients' disease-free and overall survival. Immunoreactivity for MMP-1 and MMP-3 proteins was observed in the cytoplasm of cancer cells in 30.5% and 24% of samples, respectively. Transcripts for MMP-3 mRNA were localized in stromal cells in 71.2% of cases and in cancer cells in 49% of cases. MMP-1 immunoreactivity demonstrated a statistically significant association with deeply invasive and grade III tumors versus superficial and lower grade tumors. MMP-3 protein immunoreactivity and MMP-3 mRNA immunolocalization did not associate with the parameters studied. However, MMP-3 mRNA localization in stromal cells demonstrated a borderline association with poor patients' disease-free and overall survival. In conclusion, the authors' results demonstrate a differential expression between MMP-1 and MMP-3 in bladder cancer; MMP-1 appears to participate in invasiveness and possibly in loss of differentiation in urothelial carcinomas in contrast to MMP-3.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
1541-2016
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
9
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
130-7
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:11396630-Adult,
pubmed-meshheading:11396630-Aged,
pubmed-meshheading:11396630-Aged, 80 and over,
pubmed-meshheading:11396630-Carcinoma, Transitional Cell,
pubmed-meshheading:11396630-Disease-Free Survival,
pubmed-meshheading:11396630-Female,
pubmed-meshheading:11396630-Humans,
pubmed-meshheading:11396630-Immunohistochemistry,
pubmed-meshheading:11396630-In Situ Hybridization,
pubmed-meshheading:11396630-Male,
pubmed-meshheading:11396630-Matrix Metalloproteinase 1,
pubmed-meshheading:11396630-Matrix Metalloproteinase 3,
pubmed-meshheading:11396630-Middle Aged,
pubmed-meshheading:11396630-Neoplasm Invasiveness,
pubmed-meshheading:11396630-Proportional Hazards Models,
pubmed-meshheading:11396630-Stromal Cells,
pubmed-meshheading:11396630-Survival Rate,
pubmed-meshheading:11396630-Urinary Bladder,
pubmed-meshheading:11396630-Urinary Bladder Neoplasms
|
| pubmed:year |
2001
|
| pubmed:articleTitle |
MMP-3 mRNA and MMP-3 and MMP-1 proteins in bladder cancer: a comparison with clinicopathologic features and survival.
|
| pubmed:affiliation |
Department of Pathology, Medical School, The National and Kapodistrian University of Athens, Greece. lnakopou@cc.uoa.gr
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|